Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 11, 2014, Pages E2457-E2462

  McFadden, David G ^a   Dias Santagata, Dora ^b   Sadow, Peter M ^b   Lynch, Kerry D ^b   Lubitz, Carrie ^c   Donovan, Samuel E ^a   Zheng, Zongli ^b   Le, Long ^b   Iafrate, A J ^b   Daniels, Gilbert H ^a  

^a Metabolism and Diabetes   (United States)

^b Department of Pathology ^*  (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; ALK GENE; ARTICLE; BRAF GENE; CONTROLLED STUDY; CREB3L2 GENE; FEMALE; FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA; GENE DELETION; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; ONCOGENE; ONCOGENE RAS; POINT MUTATION; PPARGAMMA GENE; PRIORITY JOURNAL; TFG GENE; THYROID PAPILLARY CARCINOMA; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; AGED; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; THYROID FOLLICULAR CARCINOMA; THYROID TUMOR;

ADULT; AGED; CARCINOMA, PAPILLARY, FOLLICULAR; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; ONCOGENE FUSION; THYROID NEOPLASMS;

EID: 84910003087     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2611     Document Type: Article

References (26)

1. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014; 140: 317-322.
2. Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev. 2013; 34: 439-455.
3. Albores-Saavedra J, Henson DE, Glazer E, Schwartz AM. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype-papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol. 2007; 18: 1-7.
4. Lin HW, Bhattacharyya N. Clinical behavior of follicular variant of papillary thyroid carcinoma: presentation and survival. Laryngoscope. 2010; 120: 712-716.
5. Daniels GH. What if many follicular variant papillary thyroid carcinomas are not malignant? A review of follicular variant papillary thyroid carcinoma and a proposal for a new classification. Endocr Pract. 2011; 17: 768-787.
6. Rivera M, Tuttle RM, Patel S, Shaha A, Shah JP, Ghossein RA. Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern). Thyroid. 2009; 19: 119-127.
7. Vivero M, Kraft S, Barletta JA. Risk stratification of follicular variant of papillary thyroid carcinoma. Thyroid. 2013; 23: 273-279.
8. Rivera M, Ricarte-Filho J, Knauf J, et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol. 2010; 23: 1191-1200.
9. Howitt BE, Jia Y, Sholl LM, Barletta JA. Molecular alterations in partially-encapsulated or well-circumscribed follicular variant of papillary thyroid carcinoma. Thyroid. 2013; 23: 1256-1262.
10. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010; 2: 146-158.
11. Kent WJ. BLAT-the BLAST-like alignment tool. Genome Res. 2002; 12: 656-664.
12. Li H, Durbin R. Fast and accurate short read alignment with Burrows- Wheeler transform. Bioinformatics. 2009; 25: 1754-1760.
13. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993; 114: 1050-1057; discussion 1057-10588.
14. Demeure MJ, Aziz M, Rosenberg R, Gurley SD, Bussey KJ, Carpten JD. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target. World J Surg. 2014; 38: 1296-1305.
15. Kelly LM, Barila G, Liu P, et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci USA. 2014; 111: 4233-4238.
16. Perot G, Soubeyran I, Ribeiro A, et al. Identification of a recurrent STRN/ALK fusion in thyroid carcinomas. PLoS One. 2014; 9: e87170.
17. Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL, El-Naggar AK. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer. 2010; 116: 2974-2983.
18. Lee SR, Jung CK, Kim TE, et al. Molecular genotyping of follicular variant of papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing. Thyroid. 2013; 23: 1416-1422.
19. Park JY, Kim WY, Hwang TS, et al. BRAF and RAS mutations in follicular variants of papillary thyroid carcinoma. Endocr Pathol. 2013; 24: 69-76.
20. Proietti A, Giannini R, Ugolini C, et al. BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features. Thyroid. 2010; 20: 1263-1270.
21. Lui WO, Zeng L, Rehrmann V, et al. CREB3L2-PPARγ fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. Cancer Res. 2008; 68: 7156-7164.
22. Ricarte-Filho JC, Li S, Garcia-Rendueles ME, et al. Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. J Clin Invest. 2013; 123: 4935-4944.
23. Hamatani K, Mukai M, Takahashi K, Hayashi Y, Nakachi K, Kusunoki Y. Rearranged anaplastic lymphoma kinase (ALK) gene in adult-onset papillary thyroid cancer amongst atomic bomb survivors. Thyroid. 2012; 22: 1153-1159.
24. Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013; 31: 1105-1111.
25. Hernández L, Pinyol M, Hernández S, et al. TRK-fused gene (TFG) is a new partner ofALKin anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood. 1999; 94: 3265-3268.
26. Greco A, Mariani C, Miranda C, et al. TheDNArearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol Cell Biol. 1995; 15: 6118-6127.